


SOP Title:	STRIPES – Randomization Procedures (taken from STRIPES study SOP)
SOP Version:	Version 6
SOP Date:	24-Nov-2015

## 1. Randomization

### 1.1. Randomization Timeline

The timeline for enrolling and randomizing a patient into the STRIPES study is shown below in Figure 1. Time Zero is the time when the patient is first started on a vasoactive infusion. **Patients must be enrolled and randomized within 6 hours of being started on a vasoactive infusion, and receive the first dose of study drug within 8 hours.**

**Figure 1. Randomization timeline for the STRIPES Study**



### 1.2. Randomization Process

Once a patient’s eligibility has been confirmed (and for sites not using a deferred consent model, once informed consent has been obtained), the Site Research Coordinator will call the pharmacy to make sure the study drug can be dispensed within the 8 hour time frame. The 8 hours starts from the time that the patient was first started on a vasoactive infusion. **Do not randomize the patient unless you have confirmed that the pharmacy can dispense the study drug on time.** The Site Research Coordinator will then logon to the study randomization webpage at <https://dms.ohri.ca/Stripes/> and complete the randomization process as described below:

- a. Log into the randomization system using your site randomization login.
- b. Click on the red “+” sign to add a new participant.

# STRIPES

https://dms.ohri.ca/STRIPES/Parti... STRIPES

Ottawa Hospital Research Institute Institut de recherche de l'Hôpital d'Ottawa

Log Out  
Welcome: Tester9  
Your Role: Data Entry  
Your Site: TEST

Home Randomization Resource

### Randomization List

(To randomize a new participant, click on the Red plus button above. To view a participant record, click on the Green arrow icon below.)

RandomNo	RandomDate	SiteNo	CreatedUser
9001	23/May/2014	9	Stripes
9002	11/Jun/2014	9	Tester9
9003	11/Jun/2014	9	Tester9

- c. Enter the participant inclusion and exclusion criteria. Once all criteria has been entered, click on “Proceed to Randomize this Participant” at the bottom of the screen.

STRIPES

Ottawa Hospital Research Institute Institut de recherche de l'Hôpital d'Ottawa

Home Randomization Resource Documents

### STRIPES STUDY ELIGIBILITY CRITERION

Inclusion Criteria: To be randomized, criterion must be **PRESENT (Yes)**

Q1. Participant's age is newborn to 17 years inclusive  Yes  No

Q2. Participant received any dose of an infusion of any one or more of the following vasoactive agents within the 6 hours prior to randomization and is still on at least one agent  
Specify type of vasoactive agent (check all that apply):

Dopamine  Epinephrine  Norepinephrine  Milrinone  Vasopressin  Phenylephrine  Other

If Other, Specify: \_\_\_\_\_

Exclusion Criteria: To be randomized, all criteria must be **ABSENT (No)**

Q1. Participant is less than 38 weeks corrected gestational age on admission  Yes  No

Q2. Participant for whom withdrawal of treatment is anticipated  Yes  No

Q3. Participant was already enrolled in the STRIPES Study  Yes  No

Q4. Participant has known or suspected hypothalamic, pituitary or adrenal disease  Yes  No

Q5. Participant received more than one dose of systemic steroids in the last 10 days or any dose in the last 24 hours  Yes  No

Q6. Participant had cardiac surgery immediately prior to admission to  Yes  No

Q7. Participant for whom primary cardiogenic shock is suspected  Yes  No

Q8. Participants for whom spinal shock is suspected  Yes  No

Q9. Participants for who hemorrhagic shock is suspected  Yes  No

**Proceed to Randomize this participant** User Local Time:= 11 Jun 2014 11:04:52

Randomization Results


- d. Note the randomization number on the screen and record the number on the pre-printed order for the study drug. This is the participant's study ID number that will be used to de-identify the participant on study documentation (e.g. eCRF). The Site Research Coordinator and the research pharmacist will also receive an email with the randomization ID number.

Q5. Participant received more than one dose of systemic steroids in the last 10 days or any dose in the last 24 hours	No
Q6. Participant had cardiac surgery immediately prior to admission to PICU	No
Q7. Participant for whom primary cardiogenic shock is suspected.	No
Q8. Participants for whom spinal shock is suspected	No
Q9. Participants for who hemorrhagic shock is suspected	No

\*\*\*Randomization Process Completed successfully!

### Randomization Results

**RANDOMIZATION NUMBER:** 9004

**RANDOMIZATION DATE:** 11 Jun 2014 11:09:11 (dd-mmm-yyyy hh:mm:ss) **Next** 

Signatory

\_\_\_\_\_  
PI Signature

\_\_\_\_\_  
Date: (dd-mmm-yyyy)

Powered by CDE

- e. Each site pharmacy will be given a randomization schema list. Pharmacy staff will match the study randomization number recorded on the pre-printed order to the site randomization schema list to determine the patient's allocated treatment.

The randomization site will be generated and maintained by the Methods Centre at OHRI. The Methods Centre will generate a randomization list stratified by site. Patients will be randomized 1:1 using random variable block sizes (2-4 patients/block).

**If you experience technical difficulties with the randomization system, contact the Methods Centre.**

**During office hours: 8:30 - 4:30 ET.**

Please email [dms@ohri.ca](mailto:dms@ohri.ca) and phone (613) 737-8899 Ext. 73804

If no one can be reached after 10 minutes, please call Douglas McGuire at (613) 737-8899 Ext. 73802

**Outside business hours:**

Please email [dvo@ohri.ca](mailto:dvo@ohri.ca)

Please have the following information ready for the Methods Centre staff (if contacting by phone) or include the following information in the email:

- Study name
- Full name
- Username
- User role (e.g. coordinator, pharmacist)
- Site name
- Site ID (Site number for the randomization system)
- Information on the issue(s)

## **2. Randomization Back-Up**

In the event that the randomization system does not work, and the issue cannot be quickly resolved by the Methods Centre, the participant should still be enrolled and randomized manually according to the following steps:

- a. Bring the pre-printed order form to pharmacy, and inform pharmacy staff that the randomization system is not working.
- b. Pharmacy staff will assign the patient the next sequential randomization ID number on the site randomization list and allocate treatment
- c. Note: Please ensure that you get the ID number from pharmacy for use on study documents and eCRF
- d. Notify the Methods Centre at [dms@ohri.ca](mailto:dms@ohri.ca) as soon as possible after enrolling patient and inform them of the randomization number that was used.
- e. The Methods Centre will adjust the web-based system so the manually assigned number will not be re-assigned at a later date.

## **3. Randomization with Pre-Made Study Packages**

For sites that pre-make study drug packages for off-hour enrolment, please proceed as follows:

- a. Pharmacy should pre-make study drug packages for the next sequential patient number on the master randomization list.
- b. To enroll the patient, the Site Coordinator should still enter the patient into the web-based randomization system as described above at the time of enrolment.
- c. The randomization system will assign the next sequential patient number on the randomization list. This number should match the number on the pre-made study drug package. All other enrolment and study drug procedures are unchanged.
- d. If the randomization system does not function at the time of enrolment, the Site Coordinator should proceed with administering the pre-made study drug package to patient. As soon as possible, contact the study coordinator and let them know the patient number that was manually assigned so that the web-based randomization system can be updated by the Methods Centre.

## **4. Blinding**

The randomization list will only be accessible to the Methods Centre at the OHRI and to the pharmacy staff at each site, and will not be seen by anyone directly involved with the study. All study personnel (the Study Coordinator, Site Research Coordinators, Site Investigators, Principal Investigator, Co-Investigators, Data Management personnel and statisticians), members of the health care team (treating physicians, and bedside nurses) and patients/families will be blinded to the study group assignment. If possible at your site, the clinical pharmacist should also be blinded to the study group assignment. If the clinical pharmacist cannot be blinded, please ensure that they are aware of the importance of not revealing the patient's allocated study treatment.